Novartis Entresto® US patent upheld by US Court of Appeals
arcticnovartis
Mon, 01/13/2025 – 07:19
Read more about Novartis Entresto® US patent upheld by US Court of Appeals
Basel, January 13, 2025 – Novartis is pleased with the dec…
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
arcticnovartis
Mon, 12/30/2024 – 06:49
Read more about Novartis intrathecal onasemnogene abeparvovec Phase III study meets p…
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
arcticnovartis
Mon, 12/30/2024 – 06:49
Read more about Novartis intrathecal onasemnogene abeparvovec Phase III study meets p…
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
arcticnovartis
Tue, 12/10/2024 – 15:04
Read more about Longer-term Novartis Kisqali® NATALEE data show…
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
arcticnovartis
Tue, 12/10/2024 – 15:04
Read more about Longer-term Novartis Kisqali® NATALEE data show…
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
arcticnovartis
Sun, 12/08/2024 – 18:34
Read more about Longer-term data for Novartis Scemblix® re…
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
arcticnovartis
Sun, 12/08/2024 – 18:34
Read more about Longer-term data for Novartis Scemblix® re…
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
arcticnovartis
Sun, 12/08/2024 – 18:34
Read more about Longer-term data for Novartis Scemblix® re…
New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
arcticnovartis
Fri, 12/06/2024 – 07:19
Read more about New Phase IIIB data shows …
Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
arcticnovartis
Wed, 11/27/2024 – 07:19
Read more about Novartis Kisqali® receives European Comm…
